From the pen to the clinic, MatMaCorp is developing handheld real time PCR systems for the point of care.
MYRTA is capable of simultaneous PCR amplification and real-time fluorescent detection, with cycle threshold (Ct) values, in under an hour
MatMaCorp’s COVID-19 2SF RNA test detects a highly conserved RNA-dependent RNA polymerase (RdRp) gene of SARS-CoV-2 and received FDA EUA to be performed on company’s Solas 8 portable platform
MatMaCorp received NIH RADx funding to scale COVID-19 testing for rural and agricultural communities
MatMaCorp’s Solas 8 portable testing machine is designed to improve on-site testing capabilities of hospital labs in rural areas. The company recently received a share of a $129.3 million federal award to further development, part of a National Institutes of Health effort to bolster testing capacity in the United States.
MatMaCorp’s COVID-19 platform recognized by NIH. Receives funding for manufacturing and scale up of Solas 8 devices and 2SF tests to support testing in rural communities.
MatMaCorp welcomes Alexi Wellman who brings extensive leadership experience and expertise in corporate finance and accounting to our Board of Directors
As the coronavirus sweeps across the globe sickening humans, scientists are making progress on developing tests that could help combat a different deadly disease: African swine fever, which has been ravaging hog herds.